While this is an obvious requirement for cancers that are being caused by other MMTV promoter-driven transgenes, it is also recommended to monitor the functionality of the Flp recombinase on all essential target alleles that contain frt sites in cancer cells that undergo neoplastic transformation and a mesenchymal transition soon after the MMTV-Flp is expressed. This evidence concerns the gene FLT1 and cancer.